10. BIBLIOGRAFIA
1) I numeri del cancro in Italia 2015. AIOM-AIRTUM. www.aiom.it
2) Perou CM, et al. Molecular portraits of human breast tumours. Nature 2000.
3) Cancer Genome Atlas Net. Comprehensive molecular portraits of human breast tumours Nature 2012 4) Goldhirsch A, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 2013 5) Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. Mol Oncol 2011.
6) Parker JS, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009.
7) Dawood S. et al.; Prognosis of women with metastatic breast cancer by HER-2 status and trastuzumab treatment: an institutional-based review JCO 2010.
8) Carter P, et al Humanization of an anti-p185her2 antibody for human cancer therapy, Proc.Natl Acad. Sci.
USA 1992
9) Slamon DJ, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER- 2/neu oncogene. Science 1987.
10) Figueroa-Magalhães MC et al., Treatment of HER2-positive breast cancer, The Breast (2013).
11) Arteaga, C. L. et al. Treatment of HER2-positive breast cancer: current status and future perspectives.
Nat. Rev. Clin. Oncol. (2012).
12) Yarden, Y. & Sliwkowski M. X. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol.(2001).
13) Spector NL, Blackwell KL. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2009.
14) Wolff AC, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 2013.
15) Wolff AC, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007.
16) Carter P, et al Humanization of an anti-p185 her2 antibody for human cancer therapy, Proc. Natl Acad.
Sci. USA 1992
17) Baselga, J. et al. Mechanism of action of trastuzumab and scientific update, Semin. Oncol, 2001
18) Vogel, C.L. et al. Efficacy and safety of Trastuzumab as a single agent in first-line treatment of HER2- overexpressing metastatic breast cancer. J. Clin. Oncol. 2002
19) Early Breast Cancer Trialist’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005.
20) Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Davies C, Godwin J, et al: Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011.
21) Romond E, et al. Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer.
N Engl J Med 2005.
22) Joensuu H, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006.
23) Perez EA, et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 2011.
24) Perez EA, et al. Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer.
J Clin Oncol 2011.
25) Piccart M, et al. Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer.First result of HERA trial. N Engl J Med 2005.
26) Goldhirsch A, et al. 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet 2013.
27) Perez EA, et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol2008.
28) Suter TM, et al. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol. 2007.
29) de Azambuja, E., Bedard, P. L., Suter, T. & Piccart-Gebhart, M. Cardiac toxicity with anti-HER-2 therapies: what have we learned so far? Target Oncol. 2009.
30) Garnock-Jones, K. P., Keating, G. M. & Scott, L. J. Trastuzumab: a review of its use as adjuvant treatment in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer. Drugs (2010).
31) Bria, E. et al. Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials. Breast Cancer Res.
Treat.(2008).
32) Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011.
33) Joensuu H, et al. Fluorouracil, epirubicina, and cyclophosphamide with either docetaxel or vinorelbina, with and without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer trial. J Clin Oncol 2009.
34) X Pivot, G Romieu, Debled M. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. Lancet Oncol 2013.
35) Gonzalez-Angulo AM, et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol 2009.
36) Curigliano G, et al. Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer. J Clin Oncol 2009.
37) Frenel JS. Impact of adjuvant trastuzumab-based chemotherapy in T1ab node-negative HER2 overexpressing breast carcinomas.J Clin Oncol 2012.
38) Joerger M, Thurlimann B, Huober J. Small HER2-positive, node-negative breast cancer: who should receive systemic adjuvant treatment? Ann Oncol 2011.
39) Jones SE, et al. Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2- amplified early stage breast cancer: a single-group, open-label, phase 2 study. Lancet Oncol. 2013.
40) Baselga J, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012.
41) Goss P, EA. Results of a randomized, double-blind, multicenter, placebo controlled study of adjuvant lapatinib in women with early-stage Erb2-overexpressing breast cancer. Lancet Oncol 2013.
42) Capelan M, et al. Pertuzumab new hope for patients with HER2-positive breast cancer. Ann Oncol 2012.
43) Lewis Phillips GD, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody cytotoxic drug conjugate. Cancer Res 2008.
44) Tolaney SM, et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.
N Engl J Med. 2015.
45) Lichter AS, et al. Mastectomy versus breast-conserving therapy in the treatment of stage I and II carcinoma of the breast: a randomized trial at the National Cancer Institute. J Clin Oncol 1992.
46) Fisher B, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998.
47) Mauri D, Pavlidis N, Ioannidis JPA. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst 2005.
48) R. Greil, The still long and winding road to neoadjuvant sytemic therapy as the standard of care in breast cancer, Breast Care, 2006.
49) http://www.aiom.it/Attivit%E0+Scientifica/Linee+guida/Neoplasie+della+mammella
50) F. Cuppone, et al., Taxanes as primary chemotherapy for early breast cancer:meta-analysis of randomized trials, Cancer, 2008.
51) Von Minckwitz G, Loibl S, Untch M. What is the current standard of care for anti-HER2 neoadjuvant therapy in breast cancer? Oncology 2012.
52) Buzdar AU, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005.
53) Gianni L, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial) a randomized controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010.
54) Buzdar AU, et al. Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial.
Lancet Oncol. 2013.
55) M. Untch, P.A, et al., Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer:
results from the TECHNO Trial of the AGO and GBG Study Groups, Journal of Clinical Oncology,2011.
56) M.Untch, et al., Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro Study, Journal of Clinical Oncology, 2010.
57) Baselga J, et al. NeoALTTO Study Team. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012.
58) Gianni L, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012.
59) Untch M, et al. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane- based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol 2012.
60) Guarneri V, et al. Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study. J Clin Oncol 2012.
61) Robidoux A, et al. Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: NSABP protocol B-41. J Clin Oncol 2012.
62) von Minckwitz G, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012.
63) Massarweh S, et al. Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer. Cancer Res 2006.
64) Shou J, et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 2004.
65) Wang YC, et al. Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers—role of estrogen receptor and HER2 reactivation. Breast Cancer Res 2011.
66) Kaufman B, et al: Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor–
positive metastatic breast cancer: Results from the randomized phase III TAnDEM Study. J Clin Oncol 2009.
67) Johnston S, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor positive metastatic breast cancer. J Clin Oncol 2009.
68) Guarneri V, et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 2006.
69) Ring AE, et al. Estrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer. Br J Cancer 2004.
70) Rimawi MF, et al. Multicenter Phase II Study of Neoadjuvant Lapatinib and Trastuzumab With Hormonal Therapy and Without Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 2- Overexpressing Breast Cancer: TBCRC 006. J Clin Oncol 2013.
71) J. S. Mieog, J. A. van der Hage, and C. J. van de Velde, Preoperative chemotherapy for women with operable breast cancer, Cochrane Database of Systematic Reviews, 2007.
72) R. Rastogi, S. J. Anderson, and H. D. Bear, Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27, Journal of Clinical Oncology, 2008.
73) Cortazar P, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014.
74) Untch M, et al. Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann Oncol 2008.
75) C. Mazouni, et al., Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome, Journal of Clinical Oncology, 2007.
76) Scaltriti M, et al.; Expression of p95HER-2, a truncated form of the HER-2 receptor, and response to anti-HER-2 therapies in breast cancer. JNCI 2007.
77) Anido J, et al. Biosynthesis of tumorigenic HER2 Cterminal fragments by alternative initiation of translation. EMBO J 2006.
78) Pedersen K, et al. A naturally occurring HER2 carboxyterminal fragment promotes mammary tumor growth and metastasis. Mol Cell Biol 2009.
79) Saez R, et al. p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer. Clin Cancer Res 2006.
80) J Sperinde, et al. Quantitation of p95HER2 in Paraffin Sections by Using a p95-Specific Antibody and Correlation with Outcome in a Cohort of Trastuzumab-Treated Breast Cancer Patients. ClinCanRes 2010.
81) R Duchnowska, et al. Quantitative Measurements of Tumoral p95HER2 Protein Expression in Metastatic Breast Cancer Patients Treated with Trastuzumab: Independent Validation of the p95HER2 Clinical Cutoff.
Clin Cancer Res 2014.
82) Parra-Palau JL, et al. A major role of p95/611-CTF, a carboxy-terminal fragment of HER2, in the down- modulation of the estrogen receptor in HER2-positive breast cancers. Cancer Res 2010.
83) Scaltriti M, et al. Clinical Benefit of Lapatinib-Based Therapy in Patients with Human Epidermal Growth Factor Receptor 2–Positive Breast Tumors Coexpressing the Truncated p95HER2 Receptor. Clin Cancer Res 2010.
84) Gomez HL, et al. Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. JClin Oncol. 2008.
85) Geyer CE, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006.
86) Montemurro F, et al. Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer. Mol Oncol. 2014.
87) Villasboas JC, et al. Correlation of quantitative p95HER2 and HER2 protein expression with pathologic complete response (pCR) in HER2-positive breast cancer patients (pts) treated with neoadjuvant (neo) trastuzumab-containing therapy. J Clin Oncol 2012.
88) Han SW, et al. Correlation of HER2, p95HER2 and HER3 expression and treatment outcome of lapatinib plus capecitabine in her2-positive metastatic breast cancer. PLoS One 2012.
89) Arribas J,et al. p95HER2 and breast cancer. Cancer Res 2011.
90) Loibl S, et al. Validation of p95 as a predictive marker for trastuzumab-based therapy in primary HER2- positive breast cancer. J Clin Oncol 2011.
91) Denkert C, et al. HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer. Breast Cancer Res 2013.
92) Molina MA, et al. Trastuzumab (Herceptin), a humanized anti-HER2 receptor monoclonal antibody, inhibits basal and activated HER2 ectodomain cleavage in breast cancer cells. Cancer Res 2001.
93) Recupero D, et al. Spontaneous and pronase-induced HER2 truncation increases the trastuzumab binding capacity of breast cancer tissues and cell lines. J Pathol 2013.
94) Scaltriti M, et al. High HER2 expression correlates with response to the combination of lapatinib and trastuzumab. Clin Cancer Res 2014.
95) Li J, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997.
96) Parsons R and Simpson, L. PTEN and cancer. Methods Mol. Biol. 2003.
97) Nagata Y, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004.
98) Fujita T, et al. PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer. Br J Cancer. 2006.
99) Berns K, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007.
100) Loibl S, et al. PIK3CA Mutations Are Associated With Lower Rates of Pathologic Complete Response to Anti–Human Epidermal Growth Factor Receptor 2 (HER2) Therapy in Primary HER2-Overexpressing Breast Cancer. J Clin Oncol 2014.
101) Saal LH, et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 2005.
102) Perez-Tenorio G, et al. PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer. Clin Cancer Res 2007.
103) Fabi A, et al. Clinical significance of PTEN and p-AKT coexpression in HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies. Oncology2010.
104) Esteva FJ, et al. PTEN, PIK3CA, p-AKT and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am J Pathol 2010.
105) Baselga J, et al. Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in HER2-positive, first-line metastatic breast cancer (MBC). Cancer Res 2012.
106) Chandarlapaty S, et al. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 2011.
107) Faratian D, at al. Systems biology reveals new strategies for personalizing cancer medicine and confirms the role of PTEN In resistance to trastuzumab. Cancer Res 2009.
108) Faratian D, et al. Sprouty 2 is an independent prognostic factor in breast cancer and may be useful in stratifying patients for trastuzumab therapy. Plos One 2011.
109) Jensen JD, et al. PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2- positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab. Ann Oncol 2012.
110) Perez EA, et al. Effect of PTEN protein expression on benefit to adjuvant trastuzumab in early stage HER2+ breast cancer in NCCTG adjuvant trial N9831. J Clin Oncol 2011.
111) Majewski IJ, et al. PIK3CA Mutations Are Associated With Decreased Benefit to Neoadjuvant Human Epidermal Growth Factor Receptor 2-Targeted Therapies in Breast Cancer. J Clin Oncol. 2015.
112) Contreras A, et al. PIK3CA mutations and/or low PTEN predict resistance to combined anti-HER2 therapy with lapatinib and trastuzumab and without chemotherapy in TBCRC006, a neoadjuvant trial of HER2-positive breast cancer patients. Cancer Res 2013.
113) O'Brien N, et al. Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib. Mol Cancer Ther 2010.
114) Dave B, et al. Loss of Phosphatase and Tensin Homolog or Phosphoinositol-3 Kinase Activation and Response to Trastuzumab or Lapatinib in Human Epidermal Growth Factor Receptor 2–Overexpressing Locally Advanced Breast Cancers. J Clin Onc 2011.
115) Wang L, et al. PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib. BMC Cancer. 2011.
116) Cizkova M, et al. Impact of PIK3CA, PTEN and RPS6 status on lapatinib treatment outcome in advanced-stage breast cancer patients. 2010.
117) P Eichhorn, et al. PI3K Hyperactivation Results in Lapatinib Resistance that is Reversed by the mTOR/PI3K Inhibitor NVP-BEZ235. Cancer Res. Nov 15.
118) Wang Y, et al. The predictive role of phosphatase and tensin homolog (PTEN) loss, phosphoinositol-3 (PI3) kinase (PIK3CA) mutation, and PI3K pathway activation in sensitivity to trastuzumab in HER2-positive breast cancer: a meta-analysis. Curr Med Res Opin. 2013.
119) Peiró G, et al. Src, a potential target for overcoming trastuzumab resistance in HER2-positive breast carcinoma. Br J Cancer. 2014.
120) Zhang S, et al. Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat Med 2011.
121) Scaltriti M, et al. Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients. Proc Natl Acad Sci USA 2011.
122) Robinson AG, et al. Molecular predictive factors in patients receiving trastuzumab-based chemotherapy for metastatic disease. Clin Breast Cancer 2006.
123) Mith BL, Chin D, et al. The efficacy of herceptin therapies is influenced by the expression of other erbB receptors, their ligands and the activation of downstream signalling proteins. Br J Cancer 2004.
124) Lu Y, et al. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 2001.
125) Reinholz MM, at al. Effect of IGF1R protein expression on benefit to adjuvant trastuzumab in early- stage HER2+ breast cancer in NCCTG N9831 trial. J Clin Oncol 2011.
126) Gianni L, et al. Neoadjuvant pertuzumab and trastuzumab: biomarker analyses of a 4-arm randomized phase II study (NeoSphere) in patients (pts) with HER2-positive breast cancer (BC). Cancer Res 2011.
127) Bianchini G, et al. Response to neoadjuvant trastuzumab and chemotherapy in ER+ and ER- HER2- positive breast cancers: gene expression analysis. J Clin Oncol 2011.
128) Brufsky A, et al. Hormone receptor status does not affect the clinical benefit of trastuzumab therapy for patients with metastatic breast cancer. Clin Breast Cancer 2005.
129) Arnould L, et al. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody- dependent cellular cytotoxicity mechanism? Br J Cancer 2006.
130) Tamura K, et al. FcgammaR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer. Ann Oncol 2011.
131) Hurvitz SA, et al. Analysis of Fcgamma receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients. Clin Cancer Res 2012.
132) Tagliabue E, et al. Activity and resistance of trastuzumab according to different clinical settings. Cancer Treatment Reviews 2012.
133) Reis-Filho JS. Next-generation sequencing. Breast Cancer Research 2009.
134) Forbes SA, et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer.
Nucleic Acids Res. 2015.
135) Cheng WC, et al. DriverDB: an exome sequencing database for cancer driver gene identification.
Nucleic Acids Research, 2014, Vol. 42, Database issue.
136) Ahmad S, Gupta S, et al. Herceptin Resistance Database for Understanding Mechanism of Resistance in Breast Cancer Patients. Scientific Report,4:4483, DOI: 10.1038/srep04483.
137) Han M, Deng HY, Jiang R. Effect of Trastuzumab on Notch-1 Signaling Pathway in Breast Cancer SK-BR3 Cells. Chin J Cancer Res, 2012.
138) Guarneri V, et al. A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy. Annals of Oncology 2009.
